ITCI Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -15.03% compared to Intra-Cellular Therapies's net margin of -49.65%. Intra-Cellular Therapies's return on equity of -10.58% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Intra-Cellular Therapies has a consensus price target of $103.21, signalling upside risk potential of 8.8%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $7.30 which suggests that it could grow by 434.43%. Given that NovaBay Pharmaceuticals has higher upside potential than Intra-Cellular Therapies, analysts believe NovaBay Pharmaceuticals is more attractive than Intra-Cellular Therapies.

Intra-Cellular Therapies has a beta of 0.704, which suggesting that the stock is 29.611% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.646, suggesting its less volatile than the S&P 500 by 35.372%.

Intra-Cellular Therapies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intra-Cellular Therapies pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Intra-Cellular Therapies quarterly revenues are $175.2M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Intra-Cellular Therapies's net income of -$26.3M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Intra-Cellular Therapies's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intra-Cellular Therapies is 15.58x versus 0.07x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Pacira BioSciences has a net margin of -15.03% compared to Intra-Cellular Therapies's net margin of -85.11%. Intra-Cellular Therapies's return on equity of -10.58% beat Pacira BioSciences's return on equity of -10.74%.

Intra-Cellular Therapies has a consensus price target of $103.21, signalling upside risk potential of 8.8%. On the other hand Pacira BioSciences has an analysts' consensus of $19.29 which suggests that it could fall by -6.56%. Given that Intra-Cellular Therapies has higher upside potential than Pacira BioSciences, analysts believe Intra-Cellular Therapies is more attractive than Pacira BioSciences.

Intra-Cellular Therapies has a beta of 0.704, which suggesting that the stock is 29.611% less volatile than S&P 500. In comparison Pacira BioSciences has a beta of 0.765, suggesting its less volatile than the S&P 500 by 23.508%.

Intra-Cellular Therapies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pacira BioSciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intra-Cellular Therapies pays -- of its earnings as a dividend. Pacira BioSciences pays out -- of its earnings as a dividend.

Intra-Cellular Therapies quarterly revenues are $175.2M, which are larger than Pacira BioSciences quarterly revenues of $168.6M. Intra-Cellular Therapies's net income of -$26.3M is higher than Pacira BioSciences's net income of -$143.5M. Notably, Intra-Cellular Therapies's price-to-earnings ratio is -- while Pacira BioSciences's PE ratio is 11.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intra-Cellular Therapies is 15.58x versus 1.62x for Pacira BioSciences. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -15.03% compared to Intra-Cellular Therapies's net margin of 25.23%. Intra-Cellular Therapies's return on equity of -10.58% beat Pfizer's return on equity of 4.63%.

Intra-Cellular Therapies has a consensus price target of $103.21, signalling upside risk potential of 8.8%. On the other hand Pfizer has an analysts' consensus of $31.78 which suggests that it could grow by 18.92%. Given that Pfizer has higher upside potential than Intra-Cellular Therapies, analysts believe Pfizer is more attractive than Intra-Cellular Therapies.

Intra-Cellular Therapies has a beta of 0.704, which suggesting that the stock is 29.611% less volatile than S&P 500. In comparison Pfizer has a beta of 0.644, suggesting its less volatile than the S&P 500 by 35.588%.

Intra-Cellular Therapies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer offers a yield of 6.29% to investors and pays a quarterly dividend of $0.42 per share. Intra-Cellular Therapies pays -- of its earnings as a dividend. Pfizer pays out 436.39% of its earnings as a dividend.

Intra-Cellular Therapies quarterly revenues are $175.2M, which are smaller than Pfizer quarterly revenues of $17.7B. Intra-Cellular Therapies's net income of -$26.3M is lower than Pfizer's net income of $4.5B. Notably, Intra-Cellular Therapies's price-to-earnings ratio is -- while Pfizer's PE ratio is 36.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intra-Cellular Therapies is 15.58x versus 2.56x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -15.03% compared to Intra-Cellular Therapies's net margin of -2357.27%. Intra-Cellular Therapies's return on equity of -10.58% beat Palatin Technologies's return on equity of --.

Intra-Cellular Therapies has a consensus price target of $103.21, signalling upside risk potential of 8.8%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1404.43%. Given that Palatin Technologies has higher upside potential than Intra-Cellular Therapies, analysts believe Palatin Technologies is more attractive than Intra-Cellular Therapies.

Intra-Cellular Therapies has a beta of 0.704, which suggesting that the stock is 29.611% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.929%.

Intra-Cellular Therapies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intra-Cellular Therapies pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Intra-Cellular Therapies quarterly revenues are $175.2M, which are larger than Palatin Technologies quarterly revenues of $350K. Intra-Cellular Therapies's net income of -$26.3M is lower than Palatin Technologies's net income of -$7.8M. Notably, Intra-Cellular Therapies's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intra-Cellular Therapies is 15.58x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.